Geode Capital Management
SANA icon

Geode Capital Management’s Sana Biotechnology SANA Stock Holding History

Geode Capital Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.6M Sell
4,650,990
-26,969
-0.6% -$93.9K ﹤0.01% 2320
2026
Q2 		$16.3M Buy
4,677,959
+495,986
+12% +$1.6M ﹤0.01% 2275
2026
Q1 		$12M Buy
4,181,973
+63,835
+2% +$251K ﹤0.01% 2277
2025
Q4 		$16.8M Buy
4,118,138
+694,606
+20% +$3.11M ﹤0.01% 2109
2025
Q3 		$12.2M Buy
3,423,532
+143,741
+4% +$520K ﹤0.01% 2304
2025
Q2 		$8.96M Buy
3,279,791
+4,523
+0.1% +$9.33K ﹤0.01% 2434
2025
Q1 		$5.5M Buy
3,275,268
+82,187
+3% +$230K ﹤0.01% 2611
2024
Q4 		$5.21M Buy
3,193,081
+26,601
+0.8% +$79.3K ﹤0.01% 2731
2024
Q3 		$13.2M Buy
3,166,480
+276,055
+10% +$1.45M ﹤0.01% 2212
2024
Q2 		$15.8M Buy
2,890,425
+473,907
+20% +$3.78M ﹤0.01% 2057
2024
Q1 		$24.2M Buy
2,416,518
+162,682
+7% +$1.22M ﹤0.01% 1805
2023
Q4 		$9.2M Buy
2,253,836
+206,248
+10% +$760K ﹤0.01% 2394
2023
Q3 		$7.93M Buy
2,047,588
+65,058
+3% +$350K ﹤0.01% 2401
2023
Q2 		$11.8M Buy
1,982,530
+201,565
+11% +$1.16M ﹤0.01% 2188
2023
Q1 		$5.82M Sell
1,780,965
-27,399
-2% -$109K ﹤0.01% 2569
2022
Q4 		$7.14M Buy
1,808,364
+109,863
+6% +$537K ﹤0.01% 2470
2022
Q3 		$10.2M Buy
1,698,501
+47,279
+3% +$341K ﹤0.01% 2241
2022
Q2 		$10.6M Buy
1,651,222
+124,511
+8% +$793K ﹤0.01% 2207
2022
Q1 		$12.6M Sell
1,526,711
-22,472
-1% -$182K ﹤0.01% 2192
2021
Q4 		$24M Buy
1,549,183
+7,551
+0.5% +$146K ﹤0.01% 1831
2021
Q3 		$34.7M Buy
1,541,632
+991,384
+180% +$20.8M ﹤0.01% 1584
2021
Q2 		$10.8M Buy
550,248
+137,811
+33% +$3.12M ﹤0.01% 2403
2021
Q1 		$13.8M Buy
+412,437
New +$13.4M ﹤0.01% 2121

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Geode Capital Management's SANA Position: Q3 2026 in Review

Geode Capital Management reduced its Sana Biotechnology (SANA) stake by 0.58% in Q3 2026, selling an estimated $93.9K and leaving 4,650,990 shares worth $13.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

Geode Capital Management first reported a position in SANA in Q1 2021 and has held it in 23 quarters since. The position peaked at $34.7M in Q3 2021. 143 funds tracked by Wall St. Rank hold SANA as of Q3 2026.

  • Geode Capital Management held 4,650,990 shares of Sana Biotechnology worth $13.6M as of Q3 2026.
  • Geode Capital Management sold 26,969 Sana Biotechnology shares in Q3 2026, an estimated $93.9K.
  • Sana Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2320 holding.
  • Geode Capital Management first reported a position in Sana Biotechnology in Q1 2021 and has held it in 23 quarters since.
  • Geode Capital Management's Sana Biotechnology position peaked at $34.7M in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Sana Biotechnology as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.